ClinicalTrials.Veeva

Menu

Examining the Validity and Reliability of the Dresden Falls Questionnaire in Patients with Parkinson's Diagnosis Living in Turkey (DREFAQ)

I

Istanbul Medeniyet University

Status

Not yet enrolling

Conditions

Parkinson Disease
Falls
Scale Reliability Validity

Treatments

Other: The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society in Parkinson patients and to make its validity and reliability in Turkish.

Study type

Observational

Funder types

Other

Identifiers

NCT06630026
2024/115 DREFAQ

Details and patient eligibility

About

The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ) to Turkish society and to make its validity and reliability in Turkish. The DREFAQ) scale developed by Frank, Anika, et al assesses falls in patients with Parkinson. It has 5 questions. This study will be conducted with Parkinson patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions. 50 participants will be included in the study. In order to evaluate the validity of the DREFAQ, the Modified Falls Efficacy Scale (MFES), which can evaluate the efficacy of falls and has been validated in Turkish, and the Parkinson's Disease Quality of Life (PDQOL) questionnaire, which can evaluate the quality of life and has been validated in Turkish, will be used. Scales will be repeated after 15 days to assess test-retest reliability.

Full description

The reliability and validity of the scale will begin with language equivalence and cultural adaptation. The scale will be translated from English to Turkish by two people who are fluent in Turkish and English. A single Turkish translation will be obtained from these two Turkish translations with a common opinion.

The scale, which has been translated into Turkish, will be translated into English by two other people who are fluent in Turkish and English. The scale translated into English will be compared with the original. If the developer of the scale, Frank, Anika, et al approves the translation of the scale, participants will be recruited for the study. In the pre-trial phase, a reassessment will be conducted with 15 participants to test the intelligibility of the scale. Based on the results of the pre-test phase, the final version of DREFAQ will be able to be modified. The data of DREFAQ are collecting through face-to-face when the patients came to the rehabilitation center. 50 participants will be included in the study.

In order to evaluate the validity of the DREFAQ, the Modified Falls Efficacy Scale (MFES), which can evaluate the efficacy of falls and has been validated in Turkish, and the Parkinson's Disease Quality of Life (PDQOL) questionnaire, which can evaluate the quality of life and has been validated in Turkish, will be used. Scales will be repeated after 15 days to assess test-retest reliability.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Individuals with a Hoehn & Yahr score between 1-4,
  • Individuals who can ambulate with or without assistive equipment,
  • Individuals with a Mini Mental State Examination score of >24,
  • Individuals with a history of falling at least once in the last year,

Exclusion criteria

  • communication or cognitive problems,
  • aphasia and speech disorders
  • unstable medical conditions

Trial design

50 participants in 1 patient group

Parkinson Patients
Description:
Parkinson patients who are aged 18-80 years with Hoehn \& Yahr scale between 1-4 and able to speak and read Turkish, will recruit to the study.
Treatment:
Other: The aim of this study is to adapt the Dresden Falls Questionnaire scale (DREFAQ)scale to Turkish society in Parkinson patients and to make its validity and reliability in Turkish.

Trial contacts and locations

1

Loading...

Central trial contact

Emel METE Research Assistant, PhD; EMEL METE, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems